Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609606 | 0.78 | CHRNB2 (0.34) | TDO2HCRTR2 | |
| SCHEMBL10144793 | 0.78 | CHRNB2 (0.34) | TDO2HCRTR2 | |
| SCHEMBL610582 | 0.78 | CHRNB2 (0.34) | TDO2HCRTR2 | |
| SCHEMBL9899326 | 0.73 | CRHR1 (0.39) | HCRTR2 | |
| SCHEMBL19241779 | 0.72 | HCRTR2 (0.40) | HCRTR2 | |
| SCHEMBL9895811 | 0.71 | LIPE (0.41) | — | |
| SCHEMBL9896546 | 0.69 | HCRTR2 (0.39) | LNPEPHCRTR2 | |
| SCHEMBL1717590 | 0.68 | HCRTR2 (0.43) | HCRTR2 | |
| SCHEMBL16906756 | 0.67 | ELOVL1 (0.42) | TDO2 | |
| SCHEMBL22547304 | 0.67 | LNPEP (0.46) | LNPEPTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470523-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | HCRTR2, HCRTR1, HTR5A | LNPEP 2763/4885TDO2 3012/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.